FEATURED COMPANIES
- Amgen Inc.
- Biocon/Mylan
- Coherus Biosciences Inc.
- Sandoz (Novartis)
- Teva Pharmaceuticals
G-CSF (Granulocyte Colony Stimulating Factors) Global Market Opportunities and Strategies to 2030: COVID -19 Impact and Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global G-CSF (Granulocyte Colony Stimulating Factors) market.
Reasons to Purchase
Description:
Where is the largest and fastest growing market for the G-CSF (Granulocyte Colony Stimulating Factors) market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The global G-CSF (Granulocyte Colony Stimulating Factors) market opportunities and strategies to 2030 report answers all these questions and many more.
The report covers the following chapters
Markets Covered:
1) By Type: Pegfilgrastim; Filgrastim; Lenograstim; Others
2) By Application: Oncology; Blood Disorders; Chronic and Autoimmune Disorders; Others
Companies Mentioned: Amgen Inc.; Coherus Biosciences Inc.; Sandoz (Novartis); Biocon/Mylan; Teva Pharmaceuticals
Countries: China, Japan, India, Australia, USA, Brazil, UK, Germany, France, Russia, South Korea, Indonesia.
Regions: Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Reasons to Purchase
- Outperform competitors using accurate up to date demand-side dynamics information.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Identify growth segments for investment.
- Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
- Create regional and country strategies on the basis of local data and analysis.
- Stay abreast of the latest customer and market research findings
- Benchmark performance against key competitors.
- Develop strategies based on likely future developments.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Gain a global perspective on the development of the market.
Description:
Where is the largest and fastest growing market for the G-CSF (Granulocyte Colony Stimulating Factors) market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The global G-CSF (Granulocyte Colony Stimulating Factors) market opportunities and strategies to 2030 report answers all these questions and many more.
The report covers the following chapters
- Executive Summary - The executive summary section of the report gives a brief overview and summary of the report
- Report Structure - This section gives the structure of the report and the information covered in the various sections.
- Introduction - The introduction section of the report gives brief introduction about segmentation by geography, segmentation by type and segmentation by application.
- Market Characteristics - The market characteristics section of the report defines and explains the G-CSF (Granolocyte Colony Stimulating Factors) market. This chapter also defines and describes goods and related services covered in the report.
- Trends and Strategies - This chapter describes the major trends shaping the global G-CSF (Granolocyte Colony Stimulating Factors) market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
- Impact of COVID-19 - This section describes the impact of COVID-19 on the G-CSF (Granolocyte Colony Stimulating Factors) market.
- Global Market Size and Growth - This section contains the global historic (2015-2020) and forecast (2020-2025), and (2025-2030) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional Analysis - This section contains the historic (2015-2020) and forecast (2020-2025), and (2025-2030) market values and growth and market share comparison by region.
- Segmentation - This section contains the market values (2015-2030) and analysis for different segments.
- Global Macro Comparison - The global G-CSF (Granolocyte Colony Stimulating Factors) market comparison with macro-economic factors gives the G-CSF (Granolocyte Colony Stimulating Factors) market size, percentage of GDP, and average G-CSF (Granolocyte Colony Stimulating Factors) market expenditure.
- Regional Market Size and Growth - This section contains the region’s market size (2020), historic (2015-2020) and forecast (2020-2025), and (2025-2030) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region. The market overview sections of the report describe the current size of the market, background information, government initiatives, regulations, regulatory bodies, associations, corporate tax structure, investments, and major companies.
- Competitive Landscape - This section covers details on the competitive landscape of the global G-CSF (Granolocyte Colony Stimulating Factors) market, estimated market shares and company profiles for the leading players.
- Key Mergers and Acquisitions - This chapter gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Market Opportunities and Strategies - This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
- Conclusions and Recommendations - This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for G-CSF (Granolocyte Colony Stimulating Factors) companies in terms of product/service offerings, geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
1) By Type: Pegfilgrastim; Filgrastim; Lenograstim; Others
2) By Application: Oncology; Blood Disorders; Chronic and Autoimmune Disorders; Others
Companies Mentioned: Amgen Inc.; Coherus Biosciences Inc.; Sandoz (Novartis); Biocon/Mylan; Teva Pharmaceuticals
Countries: China, Japan, India, Australia, USA, Brazil, UK, Germany, France, Russia, South Korea, Indonesia.
Regions: Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Amgen Inc.
- Biocon/Mylan
- Coherus Biosciences Inc.
- Sandoz (Novartis)
- Teva Pharmaceuticals
1. G-CSF (Granulocyte Colony Stimulating Factors) Market Executive Summary2. Table of Contents3. List of Figures4. List of Tables5. Report Structure
6. Introduction
7. G-CSF (Granolocyte Colony Stimulating Factors) Market Characteristics
8. G-CSF (Granulocyte Colony Stimulating Factors) Market Trends and Strategies
9. Impact of COVID-19 on the G-CSF (Granolocyte Colony Stimulating Factors) Market
10. Global G-CSF (Granulocyte Colony Stimulating Factors) Market Size and Growth
11. Global G-CSF (Granulocyte Colony Stimulating Factors) Market Segmentation
12. G-CSF (Granulocyte Colony Stimulating Factors) Market, Regional and Country Analysis
13. Asia-Pacific G-CSF (Granulocyte Colony Stimulating Factors) Market
14. Western Europe G-CSF (Granulocyte Colony Stimulating Factors) Market
15. Eastern Europe G-CSF (Granulocyte Colony Stimulating Factors) Market
16. North America G-CSF (Granulocyte Colony Stimulating Factors) Market
17. South America G-CSF (Granulocyte Colony Stimulating Factors) Market
18. Middle East G-CSF (Granulocyte Colony Stimulating Factors) Market
19. Africa G-CSF (Granulocyte Colony Stimulating Factors) Market
20. Global G-CSF (Granulocyte Colony Stimulating Factors) Market Competitive Landscape
21. Key Mergers and Acquisitions in the G-CSF (Granulocyte Colony Stimulating Factors) Market
22. G-CSF (Granulocyte Colony Stimulating Factors) Market Opportunities and Strategies
23. G-CSF (Granulocyte Colony Stimulating Factors) Market, Conclusions and Recommendations
24. Appendix
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Amgen Inc.
- Biocon/Mylan
- Coherus Biosciences Inc.
- Sandoz (Novartis)
- Teva Pharmaceuticals
This report describes and explains the global G-CSF (Granulocyte Colony Stimulating Factors) market and covers 2015 to 2020, termed the historic period, and 2020 to 2025 termed the forecast period, along with further forecasts for the period 2025-2030. The report evaluates the market across each region and for the major economies within each region.
The global G-CSF (Granulocyte Colony Stimulating Factors) market reached a value of nearly $5,005.6 million in 2020, having decreased at a compound annual growth rate (CAGR) of -5.3% since 2015, primarily due to high uptake of biosimilars in the EU and USA and COVID-19 impact. The market is expected to grow from $5,005.6 million in 2020 to $5,721.6 million in 2025 at a rate of 2.7%. The market is then expected to grow at a CAGR of 6.3% from 2025 and reach $7,761.1 million in 2030.
Growth in the historic period resulted from increase in cancer prevalence, strong economic growth in emerging markets, increased healthcare expenditure, increase in pharmaceutical R&D expenditure and government initiatives. Factor that negatively affected growth in the historic period was pricing pressures from regulators, challenges due to regulatory changes and low healthcare access.
Going forward, increasing prevalence of cancer, increasing demand for prophylaxis granulocyte colony-stimulating factor (G-CSF), rise in healthcare expenditure, high potential of emerging economies, technology advances and high penetration of the biosimilar drugs will drive the growth. Factors that could hinder the growth of the G-CSF (Granulocyte Colony Stimulating Factors) market in the future include high costs of drugs, rise in interest rates, high cost of drug development with threat of failure and coronavirus pandemic.
The G-CSF (Granulocyte Colony Stimulating Factors) market is segmented by type into pegfilgrastim, filgrastim, lenograstim and others. The pegfilgrastim market was the largest segment of the G-CSF (Granulocyte Colony Stimulating Factors) market segmented by type, accounting for 77.6% of the total in 2020. Going forward, the filgrastim segment is expected to be the fastest growing segment in the G-CSF (Granulocyte Colony Stimulating Factors) market segmented by type, at a CAGR of 5.7% during 2020-2025.
The G-CSF (Granulocyte Colony Stimulating Factors) market is segmented by application into oncology, blood disorders, chronic and autoimmune disorders and other applications. The oncology market was the largest segment of the G-CSF (Granulocyte Colony Stimulating Factors) market segmented by application, accounting for 61.7% of the total in 2020. Going forward, the oncology segment is expected to be the fastest growing segment in the G-CSF (Granulocyte Colony Stimulating Factors) market segmented by application, at a CAGR of 3.3% during 2020-2025.
The G-CSF (Granulocyte Colony Stimulating Factors) market is segmented by geography into Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.North America was the largest region in the global G-CSF (Granulocyte Colony Stimulating Factors) market, accounting for 50.1% of the total in 2020. It was followed by Western Europe, and then the other regions. Going forward, the fastest-growing regions in the G-CSF (Granulocyte Colony Stimulating Factors) market will be Middle East, and Eastern Europe, where growth will be at CAGRs of 25.9% and 11.7% respectively. These will be followed by South America, and Africa where the markets are expected to grow at CAGRs of 8.6% and 5.0% respectively.
The G-CSF (Granolocyte Colony Stimulating Factors) market is particularly prone to disruption from the coronavirus outbreak, as patients with cancer are more susceptible to viral infections, especially after chemotherapy, stem cell transplants, or surgeries. COVID-19 has caused clinical trial delays for G-CSF drugs, and has resulted in low usage of G-CSF drugs. Due to worldwide lockdown, production is also being halted which is causing supply chain issues.
The onset of the COVID-19 pandemic brought multiple complications across various markets, out of these, the G-CSF market took a hard hit. Supply chain disruption has impacted distribution and the availability of critical drugs and the delay in clinical trials along with halting of research work for G-CSF drugs has severely impacted the G-CSF market.
The G-CSF market is concentrated, with a small number of large players dominating the market. The top eight competitors in the market made up to 89.1% of the total market in 2019. The market is highly competitive. Companies in the market face completion for new product developments and technological advances. Major players in the market includes, Amgen Inc., Coherus Biosciences Inc., Sandoz (Novartis), Biocon/Mylan, Teva Pharmaceutcals Inc., Chugai Pharma Inc., Intalfarmaco Group, and Pfizer.
The top opportunities in the G-CSF (Granulocyte Colony Stimulating Factors) market segmented by type will arise in the pegfilgrastim segment, which will gain $420.6 million of global annual sales by 2025. The top opportunities in segment by application will arise in the oncology segment, which will gain $539.6 million of global annual sales by 2025. The G-CSF (Granulocyte Colony Stimulating Factors) market size will gain the most in the USA at $337.0 million.
Market-trend-based strategies for the G-CSF (Granulocyte Colony Stimulating Factors) market include investing extensively in R&D activities for the development of effective and innovative drugs, increasing focus on M&A growth strategies to expand the customer base and geographic markets, establishing strategic partnerships with the large players to expand their research and developments activities in new drug developments and focusing efforts towards the production of biosimilars for neutropenia treatment to improve revenues and product offerings.
Player-adopted strategies in the G-CSF (Granulocyte Colony Stimulating Factors) market include expanding their business presence through strategic acquisitions of emerging companies, commercialization of biosimilars, drug approvals from regulatory bodies, product expansions, and innovative product developments.
To take advantage of the opportunities, the publisher recommends the G-CSF (granulocyte colony stimulating factors) market companies to focus on research and development, acquisitions of other companies, expand in emerging markets, offering skimmed pricing, leveraging social media platforms, targeting hospitals and pharmacies to spread awareness and target geriatric populations.
The global G-CSF (Granulocyte Colony Stimulating Factors) market reached a value of nearly $5,005.6 million in 2020, having decreased at a compound annual growth rate (CAGR) of -5.3% since 2015, primarily due to high uptake of biosimilars in the EU and USA and COVID-19 impact. The market is expected to grow from $5,005.6 million in 2020 to $5,721.6 million in 2025 at a rate of 2.7%. The market is then expected to grow at a CAGR of 6.3% from 2025 and reach $7,761.1 million in 2030.
Growth in the historic period resulted from increase in cancer prevalence, strong economic growth in emerging markets, increased healthcare expenditure, increase in pharmaceutical R&D expenditure and government initiatives. Factor that negatively affected growth in the historic period was pricing pressures from regulators, challenges due to regulatory changes and low healthcare access.
Going forward, increasing prevalence of cancer, increasing demand for prophylaxis granulocyte colony-stimulating factor (G-CSF), rise in healthcare expenditure, high potential of emerging economies, technology advances and high penetration of the biosimilar drugs will drive the growth. Factors that could hinder the growth of the G-CSF (Granulocyte Colony Stimulating Factors) market in the future include high costs of drugs, rise in interest rates, high cost of drug development with threat of failure and coronavirus pandemic.
The G-CSF (Granulocyte Colony Stimulating Factors) market is segmented by type into pegfilgrastim, filgrastim, lenograstim and others. The pegfilgrastim market was the largest segment of the G-CSF (Granulocyte Colony Stimulating Factors) market segmented by type, accounting for 77.6% of the total in 2020. Going forward, the filgrastim segment is expected to be the fastest growing segment in the G-CSF (Granulocyte Colony Stimulating Factors) market segmented by type, at a CAGR of 5.7% during 2020-2025.
The G-CSF (Granulocyte Colony Stimulating Factors) market is segmented by application into oncology, blood disorders, chronic and autoimmune disorders and other applications. The oncology market was the largest segment of the G-CSF (Granulocyte Colony Stimulating Factors) market segmented by application, accounting for 61.7% of the total in 2020. Going forward, the oncology segment is expected to be the fastest growing segment in the G-CSF (Granulocyte Colony Stimulating Factors) market segmented by application, at a CAGR of 3.3% during 2020-2025.
The G-CSF (Granulocyte Colony Stimulating Factors) market is segmented by geography into Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.North America was the largest region in the global G-CSF (Granulocyte Colony Stimulating Factors) market, accounting for 50.1% of the total in 2020. It was followed by Western Europe, and then the other regions. Going forward, the fastest-growing regions in the G-CSF (Granulocyte Colony Stimulating Factors) market will be Middle East, and Eastern Europe, where growth will be at CAGRs of 25.9% and 11.7% respectively. These will be followed by South America, and Africa where the markets are expected to grow at CAGRs of 8.6% and 5.0% respectively.
The G-CSF (Granolocyte Colony Stimulating Factors) market is particularly prone to disruption from the coronavirus outbreak, as patients with cancer are more susceptible to viral infections, especially after chemotherapy, stem cell transplants, or surgeries. COVID-19 has caused clinical trial delays for G-CSF drugs, and has resulted in low usage of G-CSF drugs. Due to worldwide lockdown, production is also being halted which is causing supply chain issues.
The onset of the COVID-19 pandemic brought multiple complications across various markets, out of these, the G-CSF market took a hard hit. Supply chain disruption has impacted distribution and the availability of critical drugs and the delay in clinical trials along with halting of research work for G-CSF drugs has severely impacted the G-CSF market.
The G-CSF market is concentrated, with a small number of large players dominating the market. The top eight competitors in the market made up to 89.1% of the total market in 2019. The market is highly competitive. Companies in the market face completion for new product developments and technological advances. Major players in the market includes, Amgen Inc., Coherus Biosciences Inc., Sandoz (Novartis), Biocon/Mylan, Teva Pharmaceutcals Inc., Chugai Pharma Inc., Intalfarmaco Group, and Pfizer.
The top opportunities in the G-CSF (Granulocyte Colony Stimulating Factors) market segmented by type will arise in the pegfilgrastim segment, which will gain $420.6 million of global annual sales by 2025. The top opportunities in segment by application will arise in the oncology segment, which will gain $539.6 million of global annual sales by 2025. The G-CSF (Granulocyte Colony Stimulating Factors) market size will gain the most in the USA at $337.0 million.
Market-trend-based strategies for the G-CSF (Granulocyte Colony Stimulating Factors) market include investing extensively in R&D activities for the development of effective and innovative drugs, increasing focus on M&A growth strategies to expand the customer base and geographic markets, establishing strategic partnerships with the large players to expand their research and developments activities in new drug developments and focusing efforts towards the production of biosimilars for neutropenia treatment to improve revenues and product offerings.
Player-adopted strategies in the G-CSF (Granulocyte Colony Stimulating Factors) market include expanding their business presence through strategic acquisitions of emerging companies, commercialization of biosimilars, drug approvals from regulatory bodies, product expansions, and innovative product developments.
To take advantage of the opportunities, the publisher recommends the G-CSF (granulocyte colony stimulating factors) market companies to focus on research and development, acquisitions of other companies, expand in emerging markets, offering skimmed pricing, leveraging social media platforms, targeting hospitals and pharmacies to spread awareness and target geriatric populations.
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Amgen Inc.
- Coherus Biosciences Inc.
- Sandoz (Novartis)
- Biocon/Mylan
- Teva Pharmaceuticals
Note: Product cover images may vary from those shown
LOADING...